Labcorp (LH) to Release Earnings on Tuesday

Labcorp (NYSE:LH) is expected to issue its Q4 2025 results before the market opens on Tuesday, February 17th. Analysts expect the company to announce earnings of $3.95 per share and revenue of $3.5597 billion for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 9:00 AM ET.

Labcorp Price Performance

Shares of NYSE LH opened at $282.64 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.35 and a current ratio of 1.55. The firm’s 50-day simple moving average is $263.59 and its 200 day simple moving average is $268.62. The stock has a market cap of $23.43 billion, a price-to-earnings ratio of 27.76, a PEG ratio of 1.78 and a beta of 1.03. Labcorp has a fifty-two week low of $209.38 and a fifty-two week high of $293.72.

Labcorp Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 12th. Shareholders of record on Friday, February 27th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, February 27th. This represents a $2.88 annualized dividend and a yield of 1.0%. Labcorp’s dividend payout ratio is 28.29%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on LH shares. UBS Group dropped their target price on shares of Labcorp from $325.00 to $320.00 and set a “buy” rating for the company in a report on Wednesday, October 29th. Weiss Ratings upgraded Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday. JPMorgan Chase & Co. raised their price target on Labcorp from $317.00 to $319.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Robert W. Baird set a $313.00 price objective on shares of Labcorp in a research report on Wednesday, January 14th. Finally, Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Ten research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $300.75.

Insider Buying and Selling

In related news, EVP Jonathan C. Meltzer sold 87 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $290.42, for a total value of $25,266.54. Following the sale, the executive vice president owned 2,782 shares in the company, valued at approximately $807,948.44. This trade represents a 3.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Adam H. Schechter sold 5,273 shares of the business’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $284.38, for a total transaction of $1,499,535.74. Following the sale, the chief executive officer owned 87,343 shares of the company’s stock, valued at approximately $24,838,602.34. This represents a 5.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.84% of the stock is owned by insiders.

Institutional Trading of Labcorp

A number of hedge funds and other institutional investors have recently bought and sold shares of LH. JPL Wealth Management LLC bought a new position in Labcorp during the third quarter valued at $28,000. Headlands Technologies LLC raised its position in Labcorp by 300.0% in the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock worth $34,000 after purchasing an additional 96 shares during the period. Larson Financial Group LLC lifted its stake in Labcorp by 37.5% in the third quarter. Larson Financial Group LLC now owns 154 shares of the medical research company’s stock worth $44,000 after purchasing an additional 42 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of Labcorp by 575.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 162 shares of the medical research company’s stock valued at $41,000 after buying an additional 138 shares during the last quarter. Finally, MUFG Securities EMEA plc bought a new position in shares of Labcorp during the second quarter valued at approximately $65,000. Hedge funds and other institutional investors own 95.94% of the company’s stock.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.